Abstract

The review considers changes in the parameters of the hemostasis system in patients with COVID-19 and analyzes their practical significance. Modern approaches to prevention are considered and treatment of thrombotic/thromboembolic complications in COVID-19. Our data confirm that chronic inflammation leads to disorders of the blood coagulation system towards hypercoagulation, and subsequently to thrombosis, and the more experience and age of patients with COVID-19 and the higher the activity of the underlying disease, the more pronounced are the changes in coagulation hemostasis towards hypercoagulation.